Biopharma Antibacterial Therapeutics sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Biopharma Antibacterial Therapeutics
1.1 - About Biopharma Antibacterial Therapeutics sector
Companies in the Biopharma Antibacterial Therapeutics category discover, develop, and commercialize drugs that treat bacterial infections, including multidrug-resistant pathogens. Analysts seeking strategic buyers in this space evaluate firms advancing assets from target identification through clinical trials and regulatory approval, and supplying finished products to global markets. Their value lies in expanding treatment options, improving clinical outcomes, and addressing antimicrobial resistance for hospitals, clinicians, and public health systems.
Typical offerings span small-molecule antibiotics targeting Gram-negative and Gram-positive bacteria, beta-lactam/beta-lactamase inhibitor combinations, anti-MRSA and anti-Pseudomonas agents, and oral and IV formulations optimized for hospital and outpatient use. Some companies develop bacteriophage therapeutics, antimicrobial peptides, or monoclonal antibody anti-infectives. Capabilities include preclinical discovery platforms, IND-enabling studies, Phase I-III trial execution, cGMP manufacturing and sterile fill-finish, regulatory submissions, and lifecycle management for resistance mitigation.
Primary customers include hospitals and health systems, infectious disease specialists and clinics, and government public-health procurement bodies. Buyers seek improved clinical efficacy against resistant infections, shorter lengths of stay, reduced readmissions, and lower total cost of care. These companies also support antimicrobial stewardship and supply reliability through robust manufacturing and pharmacovigilance, enabling formulary adoption and broader access in both inpatient and community settings.
2. Buyers in the Biopharma Antibacterial Therapeutics sector
2.1 Top strategic acquirers of Biopharma Antibacterial Therapeutics companies
Insmed
- Description: Provider of biopharmaceutical therapies designed to deliver first- and best-in-class treatments for patients with serious and rare diseases, including chronic lung infections such as non-cystic fibrosis bronchiectasis and nontuberculous mycobacterial lung disease, guided by core values of collaboration, accountability, passion, respect and integrity.
- Key Products:
- FDA-approved treatment for non-cystic fibrosis bronchiectasis: First-ever therapy approved for adult and pediatric patients 12+, targeting chronic lung infection to improve outcomes and expand care options
- First-in-disease treatment for nontuberculous mycobacterial (NTM) lung disease: Therapy developed to address unmet medical need, aiming to transform patient lives through novel mechanism tailored to this rare pulmonary condition.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Biopharma Antibacterial Therapeutics sector
M&A buyer group 1: Infectious Diseases
Precigen
- Type: N/A
- Employees: ●●●●●
- Description: Provider of biotechnology solutions focused on human gene therapy and gene editing, leveraging proprietary DNA-engineering technologies to control cellular functions and develop treatments such as CAR-T therapies for acute myeloid leukemia.
- Key Products:
- PRGN-3006 CAR-T Therapy: Investigational CAR-T treatment granted orphan drug status targeting acute myeloid leukemia by genetically engineering patient T-cells to attack cancer cells and potentially improve clinical outcomes
- Proprietary DNA Engineering Platform: Suite of complementary technologies that enables precise DNA-based control over cellular functions, supporting creation of diverse gene and cell therapies
- Human Gene Editing Programs: Focused research initiatives applying advanced gene-editing techniques to develop next-generation therapeutics for multiple diseases using Precigen’s engineered cell and gene platforms
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Biopharma Antibacterial Therapeutics sector
3.1 - Buyout funds in the Biopharma Antibacterial Therapeutics sector
2.2 - Strategic buyer groups for Biopharma Antibacterial Therapeutics sector
4 - Top valuation comps for Biopharma Antibacterial Therapeutics companies
4.2 - Public trading comparable groups for Biopharma Antibacterial Therapeutics sector
Valuation benchmark group 1: Small-Molecule Pharmaceutical Manufacturing Companies
Eli Lilly
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of innovative medicines and biotechnology solutions aimed at improving global health. Utilizes advanced scientific research and development to create treatments for various medical conditions, enhancing quality of life and addressing unmet clinical needs in diverse healthcare areas.
- Key Products:
- Insulin Access Programs: Solutions to provide accessible insulin treatments for diabetes management.
- Cancer Treatments: Medicines targeted at oncology to improve patient outcomes.
- Cardiovascular Treatments: Innovative treatments for heart-related conditions.
- Immunology: Solutions addressing autoimmune diseases and enhancing immune system health.
- Neuroscience: Medications to treat neurological disorders including Alzheimer's and schizophrenia.